From: Ramez Naam (mez@apexnano.com)
Date: Sat Nov 30 2002 - 09:58:46 MST
From: Robert J. Bradbury [mailto:bradbury@aeiveos.com]
> The drug you have just described is very similar to Alteon's
> ALT-711. It is going through clinical trials to lower blood
> pressure -- but it basically prevents and/or reverses protein
> glycation.
:) In addition to being enthusiastic about this compound, I happen to
be a shareholder in Alteon. Phase IIb results are expected in Q1 and
Q2 of next year. Compounds that clear Phase II have a 70% chance of
clearing Phase III and making it to market.
fingers crossed,
mez
This archive was generated by hypermail 2.1.5 : Wed Jan 15 2003 - 17:58:30 MST